Third, we focused on osimertinib treatment without evaluating the impact of a subsequent immune checkpoint inhibitor, which is also an important treatment for patients with EGFR-mutated NSCLC [30]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.